Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 Price-to-Tangible-Book is 6.56 as of Aug. 16, 2026, which is 6% below its 10-year median of 7.01. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 701 Medical Devices & Instruments companies, NIOX Group ranks worse than 81.03% on this metric.
As of today (2026-08-16), NIOX Group's share price is $0.82. NIOX Group's Tangible Book per Share of Dec. 2025 for the quarter that ended in Dec. 2025 was $0.13. Hence, NIOX Group's Price to Tangible Book Ratio of today is 6.56.
The historical rank and industry rank for NIOX Group's Price-to-Tangible-Book or its related term are showing as below:
CSSPF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.58 Med: 7.01 Max: 23.11
Current: 7.45
During the past 13 years, NIOX Group's highest Price to Tangible Book Ratio was 23.11. The lowest was 2.58. And the median was 7.01.
CSSPF's Price-to-Tangible-Book is ranked worse than 81.03% of 701
companies
in the Medical Devices & Instruments industry
Industry Median: 2.71
vs CSSPF: 7.45
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
NIOX Group Price-to-Tangible-Book Related Terms
NIOX Group Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for NIOX Group's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, NIOX Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where NIOX Group's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
NIOX Group (CSSPF) has a Price-to-Tangible-Book of 6.56 as of Aug. 16, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on NIOX Group and its competitors. This is near median its historical median of 7.01. Over the past decade, NIOX Group's Price-to-Tangible-Book has ranged from 2.58 to 23.11. According to the industry distribution chart, NIOX Group ranks #568 out of 701 companies in the Medical Devices & Instruments industry, placing it in the top 81%.
Is NIOX Group's Price-to-Tangible-Book too high?
NIOX Group's current Price-to-Tangible-Book of 6.56 is near median its 10-year median of 7.01. Over the past 10 years, this metric has ranged from a low of 2.58 to a high of 23.11. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.71. NIOX Group's value of 6.56 is 142.1% above this industry median. Based on the distribution chart, NIOX Group ranks #568 out of 701 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #568 out of 701 companies for Price-to-Tangible-Book. This places NIOX Group in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.71. NIOX Group's value of 6.56 is 142.1% above this benchmark. Historically, NIOX Group's own Price-to-Tangible-Book has ranged from 2.58 to 23.11 over the past decade. While the company's 10-year median is 7.01 vs. the industry median of 2.71, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.71, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Price-to-Tangible-Book of 6.56 is 142.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Price-to-Tangible-Book is 6.56, which is near median its own 10-year median of 7.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.82 — trading 32.2% below its estimated fair value. The current Price-to-Tangible-Book is 6.56, which is near median its 10-year median of 7.01 and 142.1% above the Medical Devices & Instruments industry median of 2.71. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Price-to-Tangible-Book is 6.56 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 32.2% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Price-to-Tangible-Book: 6.56 (near median its 10-year median of 7.01)
GF Value™: $1.21 vs. price of $0.82 (32.2% below fair value)
Industry Position: 142.1% above the Medical Devices & Instruments median (#568 of 701)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
